{"preliminary_commentary":{"by_channel":{"x_thread":40,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05727904\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["lifileucel","pembrolizumab"]],"indication":"untreated unresectable or metastatic melanoma","name":"TILVANCE-301","nct_id":"NCT05727904","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tilvance-301-nct05727904. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Lifileucel plus Pembrolizumab","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Pembrolizumab alone with Optional Crossover Period","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-03-01","type":"ESTIMATED"},"conditions":["Metastatic Melanoma","Unresectable Melanoma","Melanoma"],"enrollment":{"count":670,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Lifileucel plus Pembrolizumab","otherNames":["LN-144","Pembrolizumab"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab with Optional Crossover Period","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-09-24","lead_sponsor":"Iovance Biotherapeutics, Inc.","official_title":"A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-03-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate and Progression Free Survival","timeFrame":"5 years total duration"}],"references":[],"start_date":{"date":"2023-03-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","url":"https://clinicaltrials.gov/study/NCT05727904"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tilvance-301-nct05727904"}